




RealRate

PHARMACEUTICAL 2022

Intra Cellular Therapies Inc
Rank 199 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Intra Cellular Therapies Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Intra Cellular Therapies Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Intra Cellular Therapies Inc is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 42% points.

The company's Economic Capital Ratio, given in the ranking table, is 318%, being 43% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	467,281
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	53,356
Liabilities, Non-Current	18,675
Other Assets	20,851
Other Compr. Net Income	-844
Other Expenses	8,040
Other Liabilities	0
Other Net Income	1,568
Other Revenues	83,803
Property and Equipment	1,791
Research and Development	88,846
Selling, General and Administrative Expense	272,611

Output Variable	Value in 1000 USD
Assets	489,922
Liabilities	72,031
Expenses	369,497
Revenues	83,803
Stockholders Equity	417,891
Net Income	-284,126
Comprehensive Net Income	-284,548
BaseVar	508,833
ECR before Limited Liability	223%
Economic Capital Ratio	318%